Neuren Pharmaceuticals Limited NEU.AX Stock
Neuren Pharmaceuticals Limited Price Chart
Neuren Pharmaceuticals Limited NEU.AX Financial and Trading Overview
| Neuren Pharmaceuticals Limited stock price | 20.43 AUD |
| Previous Close | 12.91 AUD |
| Open | 12.88 AUD |
| Bid | 12.5 AUD x 0 |
| Ask | 12.54 AUD x 0 |
| Day's Range | 12.44 - 12.96 AUD |
| 52 Week Range | 3.37 - 15.15 AUD |
| Volume | 2.37M AUD |
| Avg. Volume | 605.17K AUD |
| Market Cap | 1.62B AUD |
| Beta (5Y Monthly) | 1.637931 |
| PE Ratio (TTM) | Infinity |
| EPS (TTM) | 1.2 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.92 AUD |
NEU.AX Valuation Measures
| Enterprise Value | 1.59B AUD |
| Trailing P/E | Infinity |
| Forward P/E | 29.16279 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 104.899376 |
| Price/Book (mrq) | 38 |
| Enterprise Value/Revenue | 102.876 |
| Enterprise Value/EBITDA | -2196.727 |
Trading Information
Neuren Pharmaceuticals Limited Stock Price History
| Beta (5Y Monthly) | 1.637931 |
| 52-Week Change | 267.80% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.15 AUD |
| 52 Week Low | 3.37 AUD |
| 50-Day Moving Average | 13.69 AUD |
| 200-Day Moving Average | 9.54 AUD |
NEU.AX Share Statistics
| Avg. Volume (3 month) | 605.17K AUD |
| Avg. Daily Volume (10-Days) | 653.66K AUD |
| Shares Outstanding | 128.97M |
| Float | 105.67M |
| Short Ratio | N/A |
| % Held by Insiders | 16.80% |
| % Held by Institutions | 12.19% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 1.19% |
| Operating Margin (ttm) | -4.74% |
| Gross Margin | 17.54% |
| EBITDA Margin | -4.68% |
Management Effectiveness
| Return on Assets (ttm) | -1.098% |
| Return on Equity (ttm) | 0.45% |
Income Statement
| Revenue (ttm) | 15.42M AUD |
| Revenue Per Share (ttm) | 0.12 AUD |
| Quarterly Revenue Growth (yoy) | 382.19% |
| Gross Profit (ttm) | 2.71M AUD |
| EBITDA | -722000 AUD |
| Net Income Avi to Common (ttm) | 184K AUD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | 4157.60% |
Balance Sheet
| Total Cash (mrq) | 40.18M AUD |
| Total Cash Per Share (mrq) | 0.32 AUD |
| Total Debt (mrq) | 0 AUD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 25.772 |
| Book Value Per Share (mrq) | 0.33 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 3.6M AUD |
| Levered Free Cash Flow (ttm) | 2.59M AUD |
Profile of Neuren Pharmaceuticals Limited
| Country | Australia |
| State | VIC |
| City | Camberwell |
| Address | 697 Burke Road |
| ZIP | 3124 |
| Phone | 61 3 9092 0480 |
| Website | https://www.neurenpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Q&A For Neuren Pharmaceuticals Limited Stock
What is a current NEU.AX stock price?
Neuren Pharmaceuticals Limited NEU.AX stock price today per share is 20.43 AUD.
How to purchase Neuren Pharmaceuticals Limited stock?
You can buy NEU.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Neuren Pharmaceuticals Limited?
The stock symbol or ticker of Neuren Pharmaceuticals Limited is NEU.AX.
Which industry does the Neuren Pharmaceuticals Limited company belong to?
The Neuren Pharmaceuticals Limited industry is Biotechnology.
How many shares does Neuren Pharmaceuticals Limited have in circulation?
The max supply of Neuren Pharmaceuticals Limited shares is 129.95M.
What is Neuren Pharmaceuticals Limited Price to Earnings Ratio (PE Ratio)?
Neuren Pharmaceuticals Limited PE Ratio is 17.02083200 now.
What was Neuren Pharmaceuticals Limited earnings per share over the trailing 12 months (TTM)?
Neuren Pharmaceuticals Limited EPS is 1.2 AUD over the trailing 12 months.
Which sector does the Neuren Pharmaceuticals Limited company belong to?
The Neuren Pharmaceuticals Limited sector is Healthcare.
Neuren Pharmaceuticals Limited NEU.AX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
| S&P/ASX 300 AXKO | 7711.3 AUD 5103.78 USD |
-0.4
|
— — | 7688.2 AUD 5088.49 USD | 7743.1 AUD 5124.83 USD | — - | — — |
| S&P/ASX SMALL ORDINARIES AXSO | 3055.7 AUD 2022.44 USD |
-0.94
|
— — | 3042.1 AUD 2013.44 USD | 3084.6 AUD 2041.56 USD | — - | — — |
| ALL ORDINARIES AORD | 8014.4 AUD 5304.39 USD |
-0.44
|
— — | 7991.2 AUD 5289.03 USD | 8050.6 AUD 5328.35 USD | — - | — — |
- {{ link.label }} {{link}}